It is a long established fact that a reader of a page when looking at its layout.

    SmartVascular Dx

    We believe the current standard of care fails to accurately detect vascular disease.

    • Heart disease is the leading cause of death in the US and for most people, the first sign of heart disease is a heart attack.
    • 70% of heart attacks are caused by unstable cardiac lesion ruptures.
    • When the lesions become inflamed, they are prone to rupture causing a blood clot which blocks blood flow to the heart resulting in a heart attack.
    • 80% of premature deaths due to vascular disease are preventable with early diagnosis, management of risk factors, and lifestyle modification.

    Advantages of SmartVascular Dx:

    • A serum blood test we believe detects the risk of potential heart attacks and strokes of a vulnerable patient within the next 5 years.
    • This diagnostic test assesses vascular health by measuring protein biomarkers that indicate inflammation in arterial lining that can lead to heart attacks and strokes.
    • The test was developed through a series of longitudinal outcome-based studies with multiple institutions over a 15-year period of collaborative research representing over 40,000 patients.
    • SmartVascular Dx was independently validated at the National Institute of Health (NIH) and the National Heart, Lung, and Blood Institute (NHLBI) in the Multi-Ethnic Study of Atherosclerosis (MESA).
    References:
    • Cross DS, McCarty CA, Hytopoulos E, et al. (2012) Coronary risk assessment among intermediate risk patients using a clinical and biomarker based algorithm developed and validated in two population cohorts. CMRO Vol 28 – Issue 11
    • Younus M, Fan W, Harrington D, et al. (2019) Usefulness of a Coronary Artery Disease Predictive Algorithm to Predict Global Risk for Cardiovascular Disease and Acute Coronary Syndrome. Am J Cardiol 123(5):769-775
    • Hytopoulos E, Lee ML, Beggs M, et al. (2014) Cost effectiveness analysis of a next generation risk assessment score for cardiovascular disease. J Med Econ 17(2):132-41
    (Note, MIRISK VP is the previous name of the PULS Cardiac Test, which is now named SMART Vascular Dx™)